June 30th, 2022

A full text version of this article is available.
To access article obtain online access here or login
Primary Pulmonary Choriocarcinoma: A Case Report
Authors:  Gyorgy L. Vegh, M.D., Ph.D., Ivan Szigetvˇri, M.D., D.Sc., Ibolya Soltesz, M.D., Katalin Major, M.D., Jozsef Batorfi, M.D., Ph.D., Janos Dancso, M.D., Ph.D., Laszlo Zsirai, M.D., and Vilmos Fulop, M.D., D.Sc.
BACKGROUND: Primary pulmonary choriocarcinoma (PPC) is an extremely rare clinical entity. In contrast with gestational trophoblastic tumors that show an
extreme sensitivity for chemotherapy, extragonadal choriocarcinomas are mostly unresponsive to surgical and chemotherapeutic treatment and are associated with poor prognosis. The reason nongestational choriocarcinomas behave so differently from gestational tumors is unknown.

CASE: In the present case we report a 30-year-old female patient with primary choriocarcinoma of lung localization who was successfully treated with surgical resection and multiple cycles of combination chemotherapy. During her recovery she was followed up by human chorionic gonadotropin (hCG) titer measurement, and after 1 year of close surveillance of b-hCG levels her disease achieved complete remission.

CONCLUSION: Because of the extreme rarity of this malignancy, there are no standardized therapeutic guidelines for treatment. The first choice in treatment of PPC is surgical resection. Postoperatively chemotherapy is indicated immediately, because definitive histologic diagnosis is not essential before chemotherapy since b-hCG is a reliable tumor marker for choriocarcinoma. (J Reprod Med 2008;53:369-372)
Keywords:  choriocarcinoma, lung cancer, primary pulmonary choriocarcinoma
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from